Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration (FDA) in 2001, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Lei, Li, Yueshan, Xiong, Liang, Wang, Wenjing, Wu, Ming, Yuan, Ting, Yang, Wei, Tian, Chenyu, Miao, Zhuang, Wang, Tianqi, Yang, Shengyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165101/
https://www.ncbi.nlm.nih.gov/pubmed/34054126
http://dx.doi.org/10.1038/s41392-021-00572-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165101/
https://www.ncbi.nlm.nih.gov/pubmed/34054126
http://dx.doi.org/10.1038/s41392-021-00572-w

Ejemplares similares